Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.

You may also be interested in...



US FDA Marches Toward Record Novel Approvals With Ionis’ Tegsedi, Leadiant’s Revcovi

Complete response letter for Acacia’s Barhemsys is only rain on Oct. 5 approval parade.

Deal Watch: Endo Elbows In On Valeant’s Pursuit Of Salix

Bristol options rights to investigational prostate cancer immunotherapy, giving Bavarian Nordic additional funding to develop the candidate. Targacept finally calls it a day, in a reverse merger with Catalyst, while Arrowhead buys out the RNAi assets of Novartis.

Enzon CEO Profited While Stock Languished, DellaCamera Charges

Shareholder activist hedge fund calls a “Town Hall” to justify ousting the CEO as part of an unusual maneuver to solicit shareholder votes.

Related Content

Topics

UsernamePublicRestriction

Register

PS068846

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel